Jea Hoon Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/765544/publications.pdf

Version: 2024-02-01

102 papers	3,658 citations	147726 31 h-index	155592 55 g-index
108 all docs	108 docs citations	108 times ranked	5908 citing authors

#	Article	IF	Citations
1	Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer. JAMA - Journal of the American Medical Association, 2002, 287, 1671.	3.8	391
2	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. Journal of Clinical Oncology, 2014, 32, 3374-3382.	0.8	302
3	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 620-631.	5.1	215
4	Nanog signaling in cancer promotes stem-like phenotype and immune evasion. Journal of Clinical Investigation, 2012, 122, 4077-4093.	3.9	163
5	PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nature Communications, 2015, 6, 7769.	5.8	133
6	Clinical significance of OCT4 and SOX2 protein expression in cervical cancer. BMC Cancer, 2015, 15, 1015.	1.1	83
7	Lipocalin 2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer. Journal of Histochemistry and Cytochemistry, 2009, 57, 513-521.	1.3	77
8	Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Oncotarget, 2016, 7, 49481-49497.	0.8	76
9	Final overall survival (OS) results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation.. Journal of Clinical Oncology, 2020, 38, 6002-6002.	0.8	75
10	HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. Cancer Research, 2017, 77, 5039-5053.	0.4	73
11	Overexpression of Glucose Transporter-1 (GLUT-1) Predicts Poor Prognosis in Epithelial Ovarian Cancer. Cancer Investigation, 2013, 31, 607-615.	0.6	67
12	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget, 2015, 6, 39088-39097.	0.8	67
13	MICA/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer, 2014, 14, 957.	1.1	66
14	Clinical Approach and Surgical Strategy for Spinal Diseases in Pregnant Women. Spine, 2008, 33, E614-E619.	1.0	61
15	Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clinical Cancer Research, 2003, 9, 4782-91.	3.2	61
16	An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Research and Treatment, 2018, 50, 195-203.	1.3	59
17	Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients. Clinical Cancer Research, 2008, 14, 764-771.	3.2	57
18	Prognostic assessment of hypoxia and metabolic markers in cervical cancer using automated digital image analysis of immunohistochemistry. Journal of Translational Medicine, 2013, 11, 185.	1.8	57

#	Article	IF	Citations
19	A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecologic Oncology, 2018, 150, 247-252.	0.6	56
20	HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. Nature Communications, 2020, 11, 562.	5.8	54
21	The Korean guideline for cervical cancer screening. Journal of Gynecologic Oncology, 2015, 26, 232.	1.0	53
22	Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Human Pathology, 2013, 44, 1365-1374.	1.1	46
23	ORIGINAL ARTICLE: Endometrial Osteopontin mRNA Expression and Plasma Osteopontin Levels are Increased in Patients with Endometriosis. American Journal of Reproductive Immunology, 2009, 61, 286-293.	1.2	43
24	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecologic Oncology, 2018, 149, 381-387.	0.6	41
25	Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. Journal of Translational Medicine, 2016, 14, 124.	1.8	40
26	Serum HE4 Level is an Independent Prognostic Factor in Epithelial Ovarian Cancer. Annals of Surgical Oncology, 2012, 19, 1707-1712.	0.7	39
27	Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer. BMC Cancer, 2014, 14, 545.	1.1	39
28	Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer, 2017, 123, 263-272.	2.0	38
29	Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years. Journal of Korean Medical Science, 2010, 25, 1197.	1.1	34
30	Expression of stressâ€induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. Genes Chromosomes and Cancer, 2014, 53, 277-288.	1.5	33
31	Plasma carotenoids, retinol and tocopherol levels and the risk of ovarian cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 457-462.	1.3	32
32	Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. Journal of Clinical Investigation, 2018, 128, 4098-4114.	3.9	31
33	Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3â€“NANOG Axis. Cancer Research, 2018, 78, 2638-2653.	0.4	30
34	Downregulation of ERp57 expression is associated with poor prognosis in early-stage cervical cancer. Biomarkers, 2013, 18, 573-579.	0.9	27
35	Convergence of Plasma Metabolomics and Proteomics Analysis to Discover Signatures of High-Grade Serous Ovarian Cancer. Cancers, 2020, 12, 3447.	1.7	27
36	The role of S100A14 in epithelial ovarian tumors. Oncotarget, 2014, 5, 3482-3496.	0.8	27

#	Article	IF	Citations
37	Autoantibodies against stressâ€induced phosphoproteinâ€1 as a novel biomarker candidate for ovarian cancer. Genes Chromosomes and Cancer, 2010, 49, 585-595.	1.5	26
38	Establishment of five immortalized human ovarian surface epithelial cell lines via SV40 T antigen or HPV E6/E7 expression. PLoS ONE, 2018, 13, e0205297.	1.1	26
39	Functional polymorphism in manganese superoxide dismutase and antioxidant status: Their interactions on the risk of cervical intraepithelial neoplasia and cervical cancer. Gynecologic Oncology, 2009, 115, 272-276.	0.6	25
40	Association of isolated single umbilical artery with perinatal outcomes: Systemic review and meta-analysis. Obstetrics and Gynecology Science, 2017, 60, 266.	0.6	25
41	LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. Autophagy, 2021, 17, 1978-1997.	4.3	25
42	Treatment of the patients with abnormal cervical cytology: a "see-and-treat" versus three-step strategy. Journal of Gynecologic Oncology, 2009, 20, 164.	1.0	24
43	Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. Journal of Gynecologic Oncology, 2013, 24, 186.	1.0	24
44	Multiplication of neutrophil and monocyte counts (MNM) as an easily obtainable tumour marker for cervical cancer. Biomarkers, 2009, 14, 161-170.	0.9	23
45	MEK/ERK signaling is a critical regulator of high-risk human papillomavirus oncogene expression revealing therapeutic targets for HPV-induced tumors. PLoS Pathogens, 2021, 17, e1009216.	2.1	22
46	ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139. International Journal of Oncology, 2010, 37, 399-412.	1.4	21
47	API5 induces cisplatin resistance through FGFR signaling in human cancer cells. Experimental and Molecular Medicine, 2017, 49, e374-e374.	3.2	21
48	Accuracy of preoperative tests in clinical stage I endometrial cancer: the importance of lymphadenectomy. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 175-181.	1.3	20
49	Synaptonemal Complex Protein 3 Is a Prognostic Marker in Cervical Cancer. PLoS ONE, 2014, 9, e98712.	1.1	20
50	Molecular Characterization of a New Ovarian Cancer Cell Line, YDOV-151, Established from Mucinous Cystadenocarcinoma. Tohoku Journal of Experimental Medicine, 2009, 218, 129-139.	0.5	19
51	Preâ€treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. Journal of Obstetrics and Gynaecology Research, 2012, 38, 48-56.	0.6	19
52	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. Cancer Research and Treatment, 2018, 50, 956-963.	1.3	19
53	Current Status of Human Papillomavirus Infection and Introduction of Vaccination to the National Immunization Program in Korea: an Overview. Journal of Korean Medical Science, 2018, 33, e331.	1.1	19
54	Human Papillomavirus 16 Oncoproteins Downregulate the Expression of miR-148a-3p, miR-190a-5p, and miR-199b-5p in Cervical Cancer. BioMed Research International, 2018, 2018, 1-9.	0.9	19

#	Article	IF	Citations
55	ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer. Cancers, 2019, 11, 1553.	1.7	19
56	TOM40 Inhibits Ovarian Cancer Cell Growth by Modulating Mitochondrial Function Including Intracellular ATP and ROS Levels. Cancers, 2020, 12, 1329.	1.7	19
57	Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas. Obstetrics and Gynecology Science, 2018, 61, 344.	0.6	18
58	Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer. Yonsei Medical Journal, 2016, 57, 580.	0.9	17
59	Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer. Oncotarget, 2016, 7, 77052-77070.	0.8	17
60	The effects of polymorphisms in methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), and methionine synthase reductase (MTRR) on the risk of cervical intraepithelial neoplasia and cervical cancer in Korean women. Cancer Causes and Control, 2010, 21, 23-30.	0.8	16
61	Surgical practice patterns in endometrial cancer: results of the Korean Gynecologic Oncology Group survey. Journal of Gynecologic Oncology, 2009, 20, 107.	1.0	15
62	Prognostic Significance of AMP-Dependent Kinase Alpha Expression in Cervical Cancer. Pathobiology, 2015, 82, 203-211.	1.9	15
63	DNA Mismatch Repair Protein Immunohistochemistry and MLH1 Promotor Methylation Testing for Practical Molecular Classification and the Prediction of Prognosis in Endometrial Cancer. Cancers, 2018, 10, 279.	1.7	15
64	Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer. Cancer Genomics and Proteomics, 2019, 16, 553-562.	1.0	15
65	Combined treatment with modulated electro-hyperthermia and an autophagy inhibitor effectively inhibit ovarian and cervical cancer growth. International Journal of Hyperthermia, 2019, 36, 9-20.	1.1	15
66	CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 211-221.	0.6	15
67	Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma. Molecular Oncology, 2021, 15, 987-1004.	2.1	15
68	Osteopontin is down-regulated in hydatidiform mole. Gynecologic Oncology, 2003, 89, 134-139.	0.6	14
69	The feasibility of carboplatin-based intraperitoneal chemotherapy in ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 152, 195-199.	0.5	14
70	Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line. Molecular and Cellular Biochemistry, 2008, 319, 189-201.	1.4	13
71	Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. Clinical Chemistry and Laboratory Medicine, 2009, 47, 1005-12.	1.4	13
72	Diagnostic and Prognostic Impact of Osteopontin Expression in Endometrial Cancer. Cancer Investigation, 2009, 27, 313-323.	0.6	13

#	Article	IF	Citations
73	Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a caseâ€“control study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2012, 160, 100-105.	0.5	13
74	Elevated expression of pancreatic adenocarcinoma upregulated factor (PAUF) is associated with poor prognosis and chemoresistance in epithelial ovarian cancer. Scientific Reports, 2018, 8, 12161.	1.6	13
75	Prognostic implications of forkhead box protein O1 (FOXO1) and paired box 3 (PAX3) in epithelial ovarian cancer. BMC Cancer, 2019, 19, 1202.	1.1	13
76	SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers, 2021, 13, 1777.	1.7	13
77	Identification of Prognostic Markers of Gynecologic Cancers Utilizing Patient-Derived Xenograft Mouse Models. Cancers, 2022, 14, 829.	1.7	12
78	Prevalence and Seroprevalence of High-Risk Human Papillomavirus Infection. Obstetrics and Gynecology, 2010, 116, 932-940.	1.2	11
79	Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. British Journal of Cancer, 2018, 119, 530-537.	2.9	11
80	Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer. Cancer Genomics and Proteomics, 2020, 17, 309-319.	1.0	11
81	Clinical Significance of Microsatellite Instability in Sporadic Epithelial Ovarian Tumors. Yonsei Medical Journal, 2008, 49, 272.	0.9	9
82	Prevalence and Seroprevalence of Low-Risk Human Papillomavirus in Korean Women. Journal of Korean Medical Science, 2012, 27, 922.	1.1	9
83	The Combination of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) is an Effective Prognostic Biomarker in Cervical Cancer. International Journal of Gynecological Pathology, 2021, 40, 214-223.	0.9	9
84	Validation of a nomogram for predicting outcome of vulvar cancer patients, primarily treated by surgery, in Korean population: multicenter retrospective study through Korean Gynecologic Oncology Group (KGOG-1010). Journal of Gynecologic Oncology, 2008, 19, 191.	1.0	7
85	Multiparametric MR imaging of tumor response to intraarterial chemotherapy in orthotopic xenograft models of human metastatic brain tumor. Journal of Neuro-Oncology, 2016, 127, 243-251.	1.4	7
86	Preoperative levels of plasma micronutrients are related to endometrial cancer risk. Acta Obstetricia Et Gynecologica Scandinavica, 2009, 88, 434-439.	1.3	6
87	A Phase 2 Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy After Surgery in Patients With High-Risk Endometrial Cancer: A Korean Gynecologic Oncologic GroupÂStudy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 140-146.	0.4	6
88	Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. Gynecologic Oncology, 2016, 143, 128-134.	0.6	6
89	Bcl-2-like Protein 11 (BIM) Expression Is Associated with Favorable Prognosis for Patients with Cervical Cancer. Anticancer Research, 2017, 37, 4873-4879.	0.5	6
90	Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Cancer Science, 2021, 112, 5055-5067.	1.7	6

#	Article	IF	Citations
91	Clinical Significance of Serum Anti-Human Papillomavirus 16 and 18 Antibodies in Cervical Neoplasia. Obstetrics and Gynecology, 2013, 121, 321-329.	1.2	4
92	Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer. International Journal of Molecular Sciences, 2021, 22, 5714.	1.8	4
93	CRY1Regulates Chemoresistance in Association WithNANOGby Inhibiting Apoptosisvia STAT3Pathway in Patients With Cervical Cancer. Cancer Genomics and Proteomics, 2021, 18, 699-713.	1.0	4
94	Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Cancer Research and Treatment, 2019, 51, 112-118.	1.3	4
95	Identification of a novel gene signature in second-trimester amniotic fluid for the prediction of preterm birth. Scientific Reports, 2022, 12, 3085.	1.6	3
96	NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. Scientific Reports, 2022, 12, .	1.6	3
97	Makorin Ring Finger Protein 1 as Adjunctive Marker in Liquid-based Cervical Cytology. Medicine (United) Tj ETQq1 1 0.784314 rgBT /O	0.4	2
98	BRAK and APRIL as novel biomarkers for ovarian tumors. Biomarkers in Medicine, 2022, 16, 717-729.	0.6	2
99	Anti-cancer effects of high-dose selenium via lipid peroxidation in ovarian cancer.. Journal of Clinical Oncology, 2022, 40, e17547-e17547.	0.8	2
100	Modulated electroâ€hyperthermia with weekly paclitaxel or cisplatin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: The KGOG 3030 trial. Experimental and Therapeutic Medicine, 2021, 22, 787.	0.8	1
101	Prognostic implication of forkhead box protein O1 (FOXO1) and paired box gene 3 (PAX3) in epithelial ovarian cancer.. Journal of Global Oncology, 2019, 5, 61-61.	0.5	0
102	PACSIN3 is a novel biomarker for platinum resistance BRCA mutated platinum resistance epithelial ovarian cancer.. Journal of Clinical Oncology, 2022, 40, e17540-e17540.	0.8	0